Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
ONCOMETHYLOME SCNC [BE0003844611/MDXH]   
[02/09/2018]

ONCOMETHYLOME SCNC : MDxHealth (MDXH-BR): Building Momentum

goetzpartners securities Limited MDxHealth MDXHBR: Building Momentum 02Sep2018 / 12:33 GMT/BST Free to access research and investor meetings in a postMiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties institutional investors in the applicable jurisdiction, and not by any private individuals or other persons... See more
 
ONCOMETHYLOME SCNC [BE0003844611/MDXH]   
[27/06/2018]

ONCOMETHYLOME SCNC : MDxHealth (MDXH-BR): Prostate cancer test proves value in pre-biopsy screening

goetzpartners securities Limited MDxHealth MDXHBR: Prostate cancer test proves value in prebiopsy screening 27Jun2018 / 13:43 GMT/BST Free to access research and investor meetings in a postMiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties institutional investors in the applicable jurisdiction, and not by any... See more
 
ONCOMETHYLOME SCNC [BE0003844611/MDXH]   
[25/04/2018]

ONCOMETHYLOME SCNC : MDxHealth (MDXH-BR): Back on track in Q1

goetzpartners securities Limited MDxHealth MDXHBR: Back on track in Q1 25Apr2018 / 11:09 GMT/BST Free to access research and investor meetings in a postMiFID2 world MDxHealth MDXHBR: Back on track in Q1 Recommendation: OUTPERFORM Target Price: EUR9.00 Current Price: EUR3.75 COB on 24th April 2018 KEY TAKEAWAY Strong growth in both test volumes and revenues reported in Q1 indicates that... See more
 
ONCOMETHYLOME SCNC [BE0003844611/MDXH]   
[27/02/2018]

ONCOMETHYLOME SCNC : MDxHealth (MDXH-BR): Growth in prospect a compelling opportunity

goetzpartners securities Limited MDxHealth MDXHBR: Growth in prospect a compelling opportunity 27Feb2018 / 10:00 GMT/BST Free to access research in a postMiFID2 world MDxHealth MDXHBR: Growth in prospect a compelling opportunity Recommendation: OUTPERFORM from Under Review Target Price EUR9.00 from Under Review Current Price as at cob 26th February 2018: EUR3.43 KEY TAKEAWAY Disappointment... See more
 
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...